There New Drugs for Lowering Triglycerides
A drug that is being tested successfully lowering triglyceride levels significantly. In fact, so far there has been no successful drugs do.
Triglycerides are a form of blood fats such as cholesterol. Triglycerides produced from the food we eat everyday. In high amounts, triglycerides can cause heart problems and inflammation of the pancreas.
"Treatment for lowering triglyceride levels is highly desirable. With this new drug is promising as an effective therapy," said Dr.Joseph Witzum, a pharmacist from the University of California, San Diego.
The new drug, called ISIS 304 801, capable of lowering triglyceride levels up to 71 percent without uncomfortable side effects. Similarly, according to research results.
High triglyceride levels can be caused by genetic factors, smoking, drinking alcohol, and high-carbohydrate eating patterns.
Normal triglyceride levels are less than 150 mg/dL. However, some people have high levels, is associated with insulin resistance, metabolic syndrome, diabetes, had a history of high cholesterol and other disorders.
Metabolic syndrome is a combination of hypertension, high cholesterol, high blood sugar levels, and excess weight.
If we do a blood test, we can determine levels of bad cholesterol (LDL), good cholesterol (HDL), and triglycerides.
Therapies currently recommended doctors to lower triglyceride levels is a healthy diet and taking niaspan (also called nicotinic acid). A drug currently is, for example TriCor, can also lower triglycerides, but it did not work in some patients.
ISIS 304 801 drug works by targeting a protein, called apolipoprotin C-III, which slows the breakdown of triglycerides. This medicine will accelerate the breakdown of triglycerides so removed body fat faster.
In the early stages, the drug is tested on 57 patients who had trilgiserida levels between 350-2000 mg / dL. They were divided into two groups, there are 304 801 who received ISIS drug and placebo for 13 weeks.
As a result, patients who received the drug ISIS 304 801 decreased triglyceride levels between 31-71 percent. This is a two-stage trial of three phases required by the US authorities.